Dementia in Taiwan area

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Dementia in Taiwan area"

Transcription

1 Translational Neuroscience and Clinics ISSN print edition: ISSN electronic edition: CN print edition: /R CN electronic edition: /R DOI Vol. 2, No. 1, March 2016, pp /CN /R Dementia in Taiwan area Yuanhan Yang ( ) Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China ABSTRACT Received: 12 January 2016 Revised: 19 February 2016 Accepted: 20 February 2016 Objective: Taiwan has an increasing aging population like other developed areas. The aging population will lead to an increased prevalence of dementia. Methods: This article will reflect the status of dementia in Taiwan, including updated epidemiology, diagnosis, subtypes, and optimal treatment of dementia. Results: The article also describes and interprets the Taiwan Dementia Policy to establish a clear, large view of the current state of management of dementia in Taiwan and future policy implementation. Conclusion: A comprehensive policy to dementia, from the basic researches to clinical care and treatment, is necessary to the increased aged population in Taiwan. The authors This article is published with open access at KEYWORDS Alzheimer s disease; ascertainment of dementia 8 (AD8); acetyl cholinesterase inhibitor; dementia Citation 1 Yang YH. Dementia in Taiwan area. Transl. Neurosci. Clin. 2016, 2(1): Introduction Dementia, including Alzheimer s disease (AD), des cribes a set of symptoms severely affecting memory, orientation, reasoning, and social abilities to interfere with activities of daily living. The risk of dementia increases with age. The percentage of the elderly is increasing in Taiwan, as in most developed areas. As the population ages, dementia has become a major public health issue. 2 Epidemiology Epidemiological studies from the 1980s and 1990s reported the prevalence of dementia in Taiwan as ranging from 1.7% to 4.3% in adults aged 65 years or more. This ratio was lower than the reported preval ence in Europe and the US (5% 10%), and may be due to underreporting, higher mortality rate, or differences in race. Specifically, family members/informants may not recognize or report cognitive deficits out of respect or treat memory decline as a normal part of the aging process. Reported mortality rates in patients with de mentia in Taiwan are higher than those in most western reports, with two population based studies reporting 32% 48%, and one hospital based study showing a mean survival time for patients with AD as 4.48 years[1]. Recently, there were two studies addressing the current prevalence of dementia in Taiwan[2, 3]. A study using the ascertainment of dementia 8 (AD8) as a screening tool to screen individuals aged greater than 50 years old has found that the estimated prevalence of very mild dementia could be higher than before. Corresponding author: Yuanhan Yang, Supported by the Review Article ARTICLE INFO

2 Transl. Neurosci. Clin. 39 That study was completed by the extensive coverage of the mentality protection center (MPC), Fo Guangshan, Taiwan, and the volunteers of MPC conducted medicine related services and screening of dementia by using the AD8 that can detect dementia even at its very mild stage in the general population throughout Taiwan. From 2011 to 2013, in total, 2,171 participants, 368 in the northern, 549 in the central, 877 in the southern, and 377 in the eastern part, were recruited with the mean age being 66.9 ± 10.2 years. The ratio of patients with suspected dementia with an AD8 score 2 was 13.6% for all recruited participants, with their mean AD8 score being 2.9 ± 1.3, mean age being 69.4 ± 10.8 years, and female predominance being 73.0% (Table 1). Although this is a screening study, it has extensive coverage of Taiwan. The AD8 is capable of screening very mild dementia and the results have provided updated information on early stage dementia in Taiwan [3]. Another recently published study has suggested the prevalence rates closer to those seen in Europe and the US. A meta analysis based on DSM IV estimated the prevalence of dementia in adults aged 65 years or more to be 5.7% (95% CI ) [4]. The whole area survey in 2014 estimated the prevalence of all cause dementia at 8.04% (95% CI ), including a 3.25% (95% CI ) prevalence of very mild dementia (VMD). Meanwhile, the study estimated the prevalence of mild cognitive impairment (MCI) at 18.76% (95% CI ) (Table 2). 3 Characteristic of patients with Alzheimer s disease Like other areas, the most demented subjects were patients with AD. Not every patient with AD has been well diagnosed and treated. Most of these patients with AD were treated at medical centers and area hospitals Table 1 Ratio of suspected very mild dementia in Taiwan after screening Northern (n = 368) Central (n = 549) Southern (n = 877) Eastern (n = 377) P value (n = 2,171) n (%) 48 (13.0%) 74 (13.5%) 126 (14.4%) 48 (12.7%) (13.6%) Age, mean ± SD 70.4 ± ± ± ± ± 10.8 Female, n (%) 36 (62.5%) 55 (74.3%) 98 (77.8%) 27 (56.3%) (73.0%) AD8 total score, mean± SD 2.7 ± ± ± ± ± 1.3 Note: Adapted from Chen CH, et al. [3] Table 2 Age specific prevalence of mild cognitive impairment (MCI) and all cause dementia including very mild dementia (VMD) Age n MCI (n = 2049) Prevalence (95% CI) VMD (n = 366) Prevalence (95% CI) Dementia with CDR 1 (n = 563) Prevalence (95% CI) All dementia (VMD plus dementia with CDR 1) (n = 929 ) Prevalence (95% CI) , ( ) 1.89 ( ) 1.51 ( ) 3.40 ( ) , ( ) 1.73 ( ) 1.73 ( ) 3.46 ( ) , ( ) 3.27 ( ) 3.92 ( ) 7.19 ( ) , ( ) 4.65 ( ) 8.38 ( ) ( ) ( ) 7.56 ( ) ( ) ( ) ( ) ( ) ( ) ( ) Total 10, ( ) 3.51 ( ) 5.40 ( ) 8.91 ( ) Age adjusted prevalence (%) * ( ) 3.25 ( ) 4.79 ( ) 8.04 ( ) Age gender adjusted prevalence (%) * ( ) 3.29 ( ) 4.84 ( ) 8.13 ( ) Note: * Age adjusted prevalence was calculated using the Taiwan census data in (Adapted from Sun Y et al. [2] )

3 40 Yuanhan Yang. Dementia in Taiwan area because the treatment of AD with acetyl cholinesterase inhibitors (AchEIs) can only be reimbursed by the National Health Institute if they are treated by neurologists or psychiatrists. We launched a study several years ago to reflect the status of AD in Taiwan, registration of Alzheimer s disease [5]. Importantly, the study was extended to Beijing and Hong Kong population [6] and to other Asian areas [7]. In Taiwan, the data came from six medical centers in the northern, central, and southern parts of Taiwan to reflect the status of patients with AD. The mean age of patients with AD was 79.3 ± 7.7 years and the mean age of informants was 57.5 ± 13.7 years. Among all informants, 69% had lived with patients and 77% of recruited patients had lived with spouse, partner, or children. Regarding family history of dementia in recruited patients, 11% had one sibling with dementia, 1.8% had two siblings with dementia, and 0.5% had three or more siblings with dementia. Some patients (2.9%) reported that their fathers were diagnosed with dementia and 6.7% reported a diagnosis of dementia in their mothers [5]. 4 Diagnostic methods Commonly used assessments in Taiwan include the mini mental state examination (MMSE) [8], Alzheimer s disease assessment scale (ADAS Cog) [9], cognitive abilities screening instrument (CASI) [10], and neuropsychiatric inventory (NPI) [11]. The clinical dementia rating (CDR) scale is also used not only for staging but also for diagnosis [12]. The AD8 is used extensively as a screening tool because of its capability in screening VMD [13]. 5 Subtypes The prevalence of subtypes of dementia was similar to other reports that AD would be higher than vascular dementia (VaD) in the general population although the prevalence would vary in relation to the characteristics of the population, community based or hospital based. Two hospital based studies found higher frequencies of VaD than AD, and one community study demonstrated a predominance of AD in women and VaD in men. The lower frequency of VaD found in the community study may be due to the lack of brain imaging data, or the higher mortality rate of patients with VaD compared to patients with AD [1]. 6 Optimal treatment There are several studies conducted and completed in Taiwan to monitor the concentration of AchEIs for clinical therapeutic response [14 16]. With donepezil, we found that 60% of recruited patients with AD had improved cognition as measured by MMSE, and 57.1% had improved global status as measured by CDR sum of boxes (CDR SB). Although donepezil has been approved for the treatment of mild to moderate AD and a higher oral dosage was suggested to have a better therapeutic response in reported results, the plasma concentration of donepezil was not examined with respect to the therapeutic outcomes in other published studies. However, our studies have examined the therapeutic responses of donepezil in patients with AD in relation to their plasma concentration of donepezil. Regarding cognition, compared to the improving group, the clinically worsening group had a significantly higher donepezil concentration (P = 0.022), odds ratio (OR = 1.024, 95% CI = ) and higher initial MMSE score (P = 0.007, OR= 1.330, 95% CI = ). For global status, the initially higher CDR SB (P = 0.028, OR= 2.318, 95% CI = ) initially higher MMSE (P = 0.036, OR = 1.201, 95% CI = ), and not donepezil concentration (P = 0.883), were significantly associated with clinical worsening [15]. These important findings have highlighted the necessity of individualized treatment with optimal dosage rather than using a uniform dose. Similarly, for rivastigmine, we found that a higher rivastigmine concentration was significantly associated with improved or preserved short term memory and worsened abstraction/judgment (P = 0.021), but not with changes in other domains (P > 0.05). Therefore, the optimal concentration of rivastigmine should be quantified for each patient because of differential cognitive responses [14]. Higher NAP concentration was significantly associated with worsened abstraction/ judgment (P = 0.027), but not with changes in other domains. These therapeutic responses in cognitive domains were also different for donepezil. Among the nine cognitive domains in the cognitive ability screening instrument, the long term memory domain

4 Transl. Neurosci. Clin. 41 had the highest improvement ratio (81.1%) compared with other domains. An increased donepezil plasma concentration (mean (SD), (32.16) ng/ml) was significantly associated with the improvement of longterm memory (P = 0.045; odds ratio, 0.959; 95% CI, ) after adjusting for age, sex, education, and apo lipoprotein E genotype [16]. In those studies, we developed an optimal treatment for patients with AD such that we had a higher adherence ratio compared to other areas. For donepezil, the mean therapeutic duration was 28.0 ± 25.9 months with a maximum of 128 months and a minimum of 0.5 months. The 12 and 24 month adherence rates were 90.1% and 84.8%, respectively [17]. 7 Clinical management The currently recommended clinical guidelines for the diagnosis, assessment, and treatment of all dementia were revised and published [18]. 7.1 Donepezil For mild or moderate AD (MMSE 10 25), the use of donepezil for 12, 24, or 52 weeks improves cognitive function and global assessment (class I, level of evidence A). Daily dosage of 10 mg/day is slightly more effective than 5 mg/day but carries higher risk for adverse events, so physicians should use discretion based on the clinical presentation in dose selection. For severe AD (MMSE 0 16), donepezil also improves cognitive function and global assessment (class I, level of evidence A), and 10 mg/day is more effective than 5 mg/day. The drug also appears to improve activities of daily living (class IIa, level of evidence A), but has no effect on dementia related behavioral disturbance. 7.2 Rivastigmine For mild or moderate AD (MMSE 10 29), the use of rivastigmine at a high (6 12 mg/day) or low (1 4 mg/day) dose improves cognitive function and global assessment, and the effect is more pronounced with the higher dose (class I, level of evidence A). Activities of daily living require the high dose for significant improvement (class I, level of evidence A). Rivastigmine has a greater effect on cognitive function in patients whose disease is progressing at a faster rate (ADAS cog increase of 4 points or more in 26 weeks) as compared to those with slow disease progression (class I, level of evidence A). Early use should have a beneficial impact on cognitive function (class IIa, level of evidence B). 7.3 Galantamine For mild or moderate AD (MMSE 10 25), the use of galantamine (16 36 mg/day) improves cognitive function and global assessment (class I, level of evidence A). In particular, 16 and 24 mg/day, both significantly improve cognitive function in patients with mild AD, while only 24 mg/day produces pronounced improvement in cognitive function in patients with moderate AD (MMSE 10 18) (class I, level of evidence B). Activities of daily living improve with mg/day, but functional benefit requires mg/day (class I, level of evidence A). Goal attainment scaling is probably improved with mg/day (class IIa, level of evidence B). Of note, in Asian ethnicities or other select patients, the use of merely 8 mg/day yields improvement in cognitive function. In terms of safety, gastrointestinal adverse effects are common and dosedependent. The use of 16 mg/day may result in treatment discontinuation due to adverse events within 6 months and 24 mg/day may result in discontinuation within 3 months (class I, level of evidence A). 7.4 Memantine For moderately severe AD (MMSE 3 14), the use of memantine can improve global performance, cognitive function, activities of daily living, and behavior (class I, evidence A). Combination therapy with donepezil is superior to donepezil monotherapy (class I, evidence B). For milder AD (MMSE 10 22), memantine only improves global performance, and combination therapy with AchEI is not superior to AchEI monotherapy (class II, evidence B). The consensus for clinical management was not to differentiate between the AchEIs in terms of clinical effectiveness or preferred order of use and not to comment on when treatment should begin, end, or be switched.

5 42 Yuanhan Yang. Dementia in Taiwan area Strength of recommendation Class I consistent evidence and/or wide consensus. Class II evidence with some controversy and/or some differing opinions. IIa evidence/opinion lean toward effectiveness. IIb limited evidence/opinion supporting effectiveness. Class III evidence and/or wide consensus for ineffectiveness or harm. Grade of evidence A evidence from multiple randomized clinical trials. B evidence from a single randomized clinical trial or multiple non randomized studies. C expert consensus. 8 Medication treatment There is limited published information about the current clinical management of dementia in Taiwan. No medications are currently capable of stopping dementia or healing the existing brain damage in patients, but the AchEIs and memantine can treat the symptoms and potentially slow the progression of the disease [15]. The goal of a pharmacological treatment is to improve patients quality of life and alleviate caregivers burden. Donepezil, rivastigmine, and galantamine are approved for the treatment of mild to moderate AD (MMSE or CDR 1 2). Memantine is approved for moderate AD (MMSE or CDR 2). Donepezil or memantine (but not in combination) is approved for the treatment of severe AD (MMSE 5 9 and CDR 3). Rivastigmine is approved for the treatment of mild to moderate Parkinson s disease dementia. Treatments for VaDs are excluded because they are not reimbursed from the national health insurance system [19]. Although these therapies have been covered by the National Health Insurance Administration since 2000 (for NINDS ADRDA, DSM, or ICD established diagnoses), prior authorization and annual reauthorization are mandatory for payment. Only neurologists and psychiatrists can prescribe these medications. A survey showed that only 66.5% to 72.6% of prior authorization cases were approved. Although an appeal process is available, the majority of appeals (89.5%) upheld the denial decision [20]. The appeals were mainly denied due to lack of appropriate exclusionary data of other possible causes of dementia [1]. Patients seeking reauthorization must be followed up with updated MMSE or CDR assessments. Treatment is to be discontinued if, at the annual evaluation, there is a decrease in MMSE score of more than 2 points or increase in CDR score of 1 or more points compared to baseline [19]. Another survey showed the average duration for AchEI therapy to be approximately 14 months and that only 9.6% of patients maintained stable cognition assessments resulting in continued drug refills for more than three years [20]. Another study indicated that for the donepezil, the mean therapeutic duration was 28.0 ± 25.9 months with a maximum of 128 months and a minimum of 0.5 months. The 12 and 24 month adherence rates were 90.1% and 84.8% [17]. Such discrepancies in clinical adherence resulted from whether the study survey was conducted throughout Taiwan [20] or by a single medical center [17]. The National Health Insurance Administration in Taiwan also covers traditional Chinese medicine (TCM). One study on the utilization of TCM among patients with dementia reported that more than 40% of patients with dementia used TCM. Youngonset dementia, higher number of behavioral and psychological symptoms of dementia (BPSD), multiple chronic diseases, and poly pharmacies were independent predictors for patients with dementia seeking TCM [21]. A number of nutritional supplements and herbs have been studied for use in treating dementia, the most well known being gingko [22]. There is no data on how often these are being used in patients with dementia in Taiwan. Clinicians and patients in Taiwan are also encouraged to utilize non pharmacologic approaches such as environmental adjustment, planned activities, change in communication patterns, cognitive training, reminiscence therapy, bright light therapy, massage, music therapy, aromatherapy, pet therapy, multisensory therapy, and art therapy [23, 24] Dementia is being recognized as a growing public health issue in Taiwan. As such, the ministry of health and welfare developed the Taiwan dementia policy: A framework for prevention and care as described below [25].

6 Transl. Neurosci. Clin Taiwan dementia policy: A framework for prevention and care 9.1 Main objectives (1) Timely diagnosis and early intervention to reduce the impact of dementia. (2) Good quality services to meet the need, maintain the dignity, and improve the quality of life of people with dementia and their family. 9.2 Purposes and scope of the Taiwan strategies for dementia care 1. To improve public awareness and understanding of dementia: (1) enhancing people s knowledge and awareness about dementia, to facilitate timely referral and assessment of those at early stage of cognitive impairment or suspected of having dementia; (2) advocating educational activities related to dementia, to increase public understanding and to reduce the stigma of dementia, in order to develop a community friendly to people with dementia; (3) implementing multi dimensional educational programs through school and community activities, to promote public awareness, understanding, and care about dementia; (4) integrating the public health and social services delivering systems to assist the public in understanding and coping effectively with dementia; (5) promoting evidence based healthy life styles and social participation to lower the risk of dementia. 2. To establish a comprehensive community care network: (1) identifying early dementia symptoms for timely diagnosis and comprehensive medical care; (2) integrating community organizations such as health care services, social welfare organizations, local activity centers, local government offices, etc., to provide information about service resources and appropriate referral; (3) developing a multi dimensional, accessible community network for prevention and care while encouraging non government organizations to join and provide services; (4) providing multi dimensional care to people with dementia according to their needs in different disease stages; (5) establishing a community network to provide counseling and support for caregivers to reduce their burden; providing caregivers with education and skill training to care for individuals with dementia; (6) encouraging collaboration between local authorities and non government organizations to facilitate early intervention programs and to provide social interaction for people with early dementia, thus delaying their functional deterioration. 3. To strengthen the primary prevention and healthcare services: (1) raising the awareness of dementia as an important part of primary healthcare; increasing primary healthcare worker s competence in evaluating dementia; (2) enhancing primary healthcare workers understanding of the need of dementia care and to provide appropriate referral; (3) integrating services within the healthcare system to implement accessible network for evaluation and treatment of dementia in rural and urban areas; (4) assisting individuals with dementia to receive early intervention and appropriate treatment based on their stage of dementia. 4. To expand human resources and enhance professional competence: (1) providing education and training for personnel and volunteers at government departments, community organizations, schools, and job settings, etc., to promote their understanding and involvement of dementia; (2) connecting local government and non government organizations to educate the seed trainers and to provide community education about dementia to enhance people s understanding and involvement; (3) incorporating knowledge and skill of prevention, treatment, and care of dementia into the professional training of medical staff, social workers, and nursing aides. 5. To strengthen inter departmental cooperation and resource integration: (1) promoting cooperation between departments to advocate prevention, treatment, and early diagnosis of dementia; (2) integrating dementia related agenda across departments to develop effective strategies; (3) establishing mechanisms to integrate resources across departments to develop multi dimensional services for individuals with dementia and their family; (4) enhancing cooperation between the government and NGOs to provide services for individuals with dementia and advocate relevant policies; (5) establishing unified service window for integrated evaluation, care plan, and referral for individuals with dementia.

7 44 Yuanhan Yang. Dementia in Taiwan area 6. To encourage dementia research and international cooperation: (1) encouraging cross disciplinary and cross institutional integrated researches and evidencebased researches in dementia prevention and management, and to develop appropriate policy according to the evidence obtained in the researches; (2) regular survey of dementia prevalence at national and community level, as well as long term follow up, for policy making and advocacy; (3) encouraging research on medical care and human rights protection for individuals with dementia, including prevention, screening instrument, etiology, clinical course, prognosis, medical and non medical interventions, etc.; (4) encouraging people in related disciplines to conduct or participate in international researches or conferences about prevention and medical care of dementia. 7. To protect human rights of individuals with dementia and their family: (1) providing services for dementia prevention and care to all individuals, regardless of age, gender, and race, with equal opportunity to access related information, support, and adequate care; (2) reviewing current law to ensure rights of individuals with dementia and their caregivers; (3) developing quality indices of dementia care and building a supervision/appraisal system for services; (4) engaging non government organizations in discussions on dementia related issues, such as ethics, law, human rights protection and promotion; (5) consulting individuals with dementia and their family while making related policy. 10 Conclusion Medical treatment of dementia is most likely underutilized in Taiwan, and the state of current clinical management is unclear. As the impact of dementia continues to increase, a holistic approach as outlined in the Taiwan dementia policy is not only crucial but its implementation also warrants careful follow up. A more comprehensive clinical guideline that addresses prevention, diagnosis, care pathways, and use of nutritional supplements, herbs, and non pharmacologic treatment approaches is needed. Research on treatment utilization patterns, including complementary and alternative therapies, as well as the type and quality of care received by institutionalized patients with dementia, will be important for establishing a clearer, larger picture of the current state of management in Taiwan and guiding evidence based clinical care and future policy implementation. References [1] Fuh JL, Wang SJ. Dementia in Taiwan: Past, present, and future. Acta Neurol Taiwan 2008, 17(3): [2] Sun Y, Lee HJ, Yang SC, Chen TF, Lin KN, Lin CC, Wang PN, Tang LY, Chiu MJ. A nationwide survey of mild cognitive impairment and dementia, including very mild dementia. PLoS One 2014, 9(6): e [3] Chen CH, Wang LC, Ma TC, Yang YH. A walk-in screening of dementia in the general population in Taiwan. Sci World J 2014, 2014: Article ID [4] Wu YT, Lee HY, Norton S, Chen CF, Chen HX, He CL, Fleming J, Matthews FE, Brayne C. Prevalence studies of dementia in Mainland China, Hong Kong and Taiwan: A systematic review and meta-analysis. PLoS One 2013, 8(6): e [5] Wang WF, Chiu PY, Lin YT, Hu CJ, Fuh JL, Yang YH. Registration of Alzheimer s disease in Taiwan: Patient and informant. Am J Alzheimers Dis Other Demen 2014, 29(1): [6] Yang YH, Wang H, Lam L, Chan WC, Yu X, Li T, Wang WF, Chiu PY, Lin YT, Hu CJ, Fuh JL, Morris JC. Characteristics of Alzheimer s disease among patients in Taiwan, Hong Kong, and Beijing. J Alzheimers Dis 2014, 42(1): [7] Yang YH, Meguro K, Kim SY, Shim YS, Yu X, Chen CL, Wang H, Lam L, Senanarong V, Dominguez J, Lu PY, Lin YT, Hu CJ, Chiu PY, Fuh JL, Wang WF, Yu BC, Li T, Wang MW, Situmeang RF, Jang JW, Zhang J, Chan WC, Zhou YY, Lou HL, Zhang L, Ye M, Chen X. Impact of Alzheimer s disease in nine Asian Countries. Gerontology, in press, DOI / [8] Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12(3): [9] Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer s disease. Am J Psychiatry 1984, 141(11): [10] Lin KN, Wang PN, Liu CY, Chen WT, Lee YC, Liu HC. Cutoff scores of the cognitive abilities screening instrument, Chinese version in screening of dementia. Dement Geriatr Cogn Disord 2002, 14(4):

8 Transl. Neurosci. Clin. 45 [11] Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994, 44(12): [12] Morris JC. The clinical dementia rating (CDR): Current version and scoring rules. Neurology 1993, 43(11): [13] Yang YH, Galvin JE, Morris JC, Lai CL, Chou MC, Liu CK. Application of AD8 questionnaire to screen very mild dementia in Taiwanese. Am J Alzheimers Dis Other Demen 2011, 26(2): [14] Chou MC, Chen CH, Liu CK, Chen SH, Wu SJ, Yang YH. Concentrations of rivastigmine and NAP and the cognitive response in Taiwanese Alzheimer s disease patients. J Alzheimers Dis 2012, 31(4): [15] Yang YH, Wu SL, Chou MC, Lai CL, Chen SH, Liu CK. Plasma concentration of donepezil to the therapeutic response of Alzheimer s disease in Taiwanese. J Alzheimers Dis 2011, 23(3): [16] Yang YH, Chen CH, Chou MC, Li CH, Liu CK, Chen SH. Concentration of donepezil to the cognitive response in Alzheimer disease. J Clin Psychopharmacol 2013, 33(3): [17] Chang YP, Yang CH, Chou MC, Chen CH, Yang YH. Clinical compliance of donepezil in treating Alzheimer s disease in Taiwan. Am J Alzheimers Dis Other Demen 2015, 30(4): [18] Guideline subcommittee of the Taiwan dementia society. Guidelines for the medical treatment of patients with Alzheimer s disease. Acta Neurol Taiwan 2011, 20(2): [19] National Health Insurance Administration. National Health Insurance Administration payment guidelines for drugs acting on the nervous system [Online]. National Health Insurance Administration, webdata/webdata.aspx?menu=21&menu_id=713&webdata_ id=2919. [20] Sun Y, Lai MS, Lu CJ, Chen RC. How long can patients with mild or moderate Alzheimer s dementia maintain both the cognition and the therapy of cholinesterase inhibitors: A national population-based study. Eur J Neurol 2008, 15(3): [21] Lin SK, Tsai YT, Lai JN, Wu CT. Demographic and medication characteristics of traditional Chinese medicine users among dementia patients in Taiwan: A nationwide database study. J Ethnopharmacol 2015, 161: [22] National Center for Complementary and Integrative Health. Dietary supplements and cognitive function, Dementia, and Alzheimer s disease [Online]. National Center for Complementary and Integrative Health, health/providers/digest/alzheimers.htm. [23] Taiwan Alzheimer Disease association website. [24] Li CH, Liu CK, Yang YH, Chou MC, Chen CH, Lai CL. Adjunct effect of music therapy on cognition in Alzheimer s disease in Taiwan: A pilot study. Neuropsychiatr Dis Treat 2015, 11: [25] Taiwan Ministry of Health and Welfare. Taiwan dementia policy: A framework for prevention and Care [Online]. Taiwan Ministry of Health and Welfare, http: // 475&fod_list_no=5160&doc_no=46373&rn=

Cognitive Abilities Screening Instrument, Chinese Version 2.0 (CASI C-2.0): Administration and Clinical Application

Cognitive Abilities Screening Instrument, Chinese Version 2.0 (CASI C-2.0): Administration and Clinical Application Continuing Medical Education 180 Cognitive Abilities Screening Instrument, Chinese Version 2.0 (CASI C-2.0): Administration and Clinical Application Ker-Neng Lin 1,2, Pei-Ning Wang 1,3, Hsiu-Chih Liu 1,3,

More information

NEUROPSYCHOMETRIC TESTS

NEUROPSYCHOMETRIC TESTS NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract

More information

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and

More information

Literature Scan: Alzheimer s Drugs

Literature Scan: Alzheimer s Drugs Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Known as both a thief and murderer,

Known as both a thief and murderer, &A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer

More information

Christy Pu Institutes Degree Department Period National Yang-Ming University (Taiwan)

Christy Pu Institutes Degree Department Period National Yang-Ming University (Taiwan) Christy Pu cypu@ym.edu.tw Degree Institutes Degree Department Period National Yang-Ming University (Taiwan) PhD Public Health 09/2005~06/2008 University of Oxford (UK) MSc Economics 08/2002~07/2003 University

More information

Dementia in Taiwan: Past, Present, and Future

Dementia in Taiwan: Past, Present, and Future Review Article 153 Dementia in Taiwan: Past, Present, and Future Jong-Ling Fuh and Shuu-Jiun Wang Abstract- The percentage of Taiwanese aged 65 years and older has been increasing over the past 27 years,

More information

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia 86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Atri A, Frölich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on in cognition in patients with Alzheimer disease: three randomized clinical

More information

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal

More information

UDS Progress Report. -Standardization and Training Meeting 11/18/05, Chicago. -Data Managers Meeting 1/20/06, Chicago

UDS Progress Report. -Standardization and Training Meeting 11/18/05, Chicago. -Data Managers Meeting 1/20/06, Chicago UDS Progress Report -Standardization and Training Meeting 11/18/05, Chicago -Data Managers Meeting 1/20/06, Chicago -Training material available: Gold standard UDS informant and participant interviews

More information

Understanding of Senile Dementia by Children and Adolescents: Why Grandma Can t Remember Me?

Understanding of Senile Dementia by Children and Adolescents: Why Grandma Can t Remember Me? 138 Understanding of Senile Dementia by Children and Adolescents: Why Grandma Can t Remember Me? Jong-Ling Fuh 1, Shuu-Jiun Wang 1, and Kai-Di Juang 2 Abstract- Background: The present study sought to

More information

NEXT-Link DEMENTIA. A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES.

NEXT-Link DEMENTIA. A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES. NEXT-Link DEMENTIA A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES. NEXT-Link DEMENTIA NEXT-Link DEMENTIA is a network of Danish

More information

RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH

RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of

More information

Baseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston

Baseline Characteristics of Patients Attending the   Memory Clinic Serving the South Shore of Boston Article ID: ISSN 2046-1690 Baseline Characteristics of Patients Attending the www.thealzcenter.org Memory Clinic Serving the South Shore of Boston Corresponding Author: Dr. Anil K Nair, Chief of Neurology,

More information

Publications: Wang LJ Wang LJ Wang LJ Wang LJ Wang LJ Wang LJ Wang LJ Wang LJ Wang LJ

Publications: Wang LJ Wang LJ Wang LJ Wang LJ Wang LJ Wang LJ Wang LJ Wang LJ Wang LJ Publications: 1. Wang LJ, Huang YS. Hsiao CC. Chen CK* (2012). The trend in morning levels of salivary cortisol in children with ADHD during six-months of methylphenidate treatment. J Attention Disorders.

More information

Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic

Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic Original Articles 179 Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic Ching-Sen Shih 1, Sui-Hing Yan 2, Ying-Hoo Ho 1, Yuh-Te Lin 1, Jie-Yuan Li 1, and Yuk-Keung Lo 1 Abstract-

More information

Month/Year of Review: September 2013 Date of Last Review: February 2012

Month/Year of Review: September 2013 Date of Last Review: February 2012 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights

More information

Neurocognitive Disorders Research to Emerging Therapies

Neurocognitive Disorders Research to Emerging Therapies Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia

More information

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Dementia: the management of dementia, including the use of antipsychotic medication in older people 1.1 Short title Dementia 2 Background

More information

The prevalence of dementia in the People s Republic of China: a systematic analysis of studies

The prevalence of dementia in the People s Republic of China: a systematic analysis of studies Age and Ageing 2007; 36: 619 624 The Author 2007. Published by Oxford University Press on behalf of the British Geriatrics Society. doi:10.1093/ageing/afm128 All rights reserved. For Permissions, please

More information

Effect of neuropsychiatric symptoms of Alzheimer's disease on Chinese and American caregivers

Effect of neuropsychiatric symptoms of Alzheimer's disease on Chinese and American caregivers INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2002; 17: 29±34. DOI: 10.1002/gps.510 Effect of neuropsychiatric symptoms of Alzheimer's disease on Chinese and American caregivers

More information

Appendix K: Evidence review flow charts

Appendix K: Evidence review flow charts K.1 Dementia diagnosis K.1.1 Dementia diagnosis What are the most effective methods of primary assessment to decide whether a person with suspected dementia should be referred to a dementia service? What

More information

Recommendations on Screening for Cognitive Impairment in Older Adults 2015

Recommendations on Screening for Cognitive Impairment in Older Adults 2015 Recommendations on Screening for Cognitive Impairment in Older Adults 2015 Canadian Task Force on Preventive Health Care (CTFPHC) Putting Prevention into Practice Canadian Task Force on Preventive Health

More information

QUESTIONNAIRE: Finland

QUESTIONNAIRE: Finland QUESTIONNAIRE: Finland To put the assessment and management of behavioural disorders into a broader context of social and health policy and services in Finland, some background information is presented.

More information

Research Article Screening Dementia in the Outpatient Department: Patients at Risk for Dementia

Research Article Screening Dementia in the Outpatient Department: Patients at Risk for Dementia e Scientific World Journal, Article ID 138786, 6 pages http://dx.doi.org/10.1155/2014/138786 Research Article Screening Dementia in the Outpatient Department: Patients at Risk for Dementia Shu-Yu Tai,

More information

COGNOS. Care for people with Cognitive dysfunction A National Observational Study. Professor Dr Jan De Lepeleire COGNOS members

COGNOS. Care for people with Cognitive dysfunction A National Observational Study. Professor Dr Jan De Lepeleire COGNOS members COGNOS Care for people with Cognitive dysfunction A National Observational Study Professor Dr Jan De Lepeleire COGNOS members Luxembourg Alzheimer Europe 2010 The Careplan in Belgium Requirements for reimbursement

More information

Families Dealing with Dementia: Insights from Mainland China and Hong Kong

Families Dealing with Dementia: Insights from Mainland China and Hong Kong Families Dealing with Dementia: Insights from Mainland China and Hong Kong Dolores Gallagher- Thompson, Ph.D. Professor of Research Dept. of Psychiatry & Behavioral Sciences Stanford Univ. School of Medicine

More information

Probable Early-onset Alzheimer s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies

Probable Early-onset Alzheimer s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies Case Report Taiwanese Journal of Psychiatry (Taipei) Vol. 25 No. 1 2011 45 Probable Early-onset Alzheimer s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies Sin-Yi Chen, M.D. 1, Yuan-Han

More information

The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables

The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2005; 20: 531 536. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/gps.1317 The course of neuropsychiatric

More information

Dementia. Presented By Jennifer L. Nanson

Dementia. Presented By Jennifer L. Nanson Dementia Presented By Jennifer L. Nanson Dementia QuickTime and a decompressor are needed to see this picture. Dementia: Current Definition DSM-IV-TR Does not imply a prognosis Refers to a framework of

More information

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences

More information

Chia-Lin Li, Ph.D. Professor Department of Health Care Management College of Management Chang Gung University

Chia-Lin Li, Ph.D. Professor Department of Health Care Management College of Management Chang Gung University Chia-Lin Li, Ph.D. Professor Department of Health Care Management College of Management Chang Gung University clli@mail.cgu.edu.tw Academic Background Ph.D. Institute of Public Health, National Yang-Ming

More information

Dementia Care Pathway

Dementia Care Pathway Document level: West Locality Code: CC41 Issue number: 1 Dementia Care Pathway Lead executive Authors details Type of document Target audience Document purpose Medical Director Dr Anushta Sivananthan Dr

More information

Screening for Normal Cognition, Mild Cognitive Impairment, and Dementia with the Korean Dementia Screening Questionnaire

Screening for Normal Cognition, Mild Cognitive Impairment, and Dementia with the Korean Dementia Screening Questionnaire ORIGINAL ARTICLE https://doi.org/10.30773/pi.2017.08.24 Print ISSN 1738-3684 / On-line ISSN 1976-36 OPEN ACCESS Screening for Normal Cognition, Mild Cognitive Impairment, and Dementia with the Korean Dementia

More information

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111)

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111) National Institute for Health and Clinical Excellence Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111) Response

More information

Severity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in Taiwan

Severity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in Taiwan Original article Severity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in Taiwan Si-Sheng Huang 1, Wen-Fu Wang 2, Yi-Cheng Liao 1 1 Department of

More information

HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?

HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of

More information

The Diabetes Epidemic in Korea

The Diabetes Epidemic in Korea Review Article Endocrinol Metab 2016;31:349-33 http://dx.doi.org/.3803/enm.2016.31.3.349 pissn 2093-96X eissn 2093-978 The Diabetes Epidemic in Korea Junghyun Noh Department of Internal Medicine, Inje

More information

SHARED CARE OF MCI/EARLY DEMENTIA

SHARED CARE OF MCI/EARLY DEMENTIA SHARED CARE OF MCI/EARLY DEMENTIA BY DR. OLUFEMI BANJO MD, DTM, DCP, DIPA&DS, DHM, M.Med.Sc, FRCP(C) GERIATRIC PSYCHIATRIST. ASSISTANT MEDICAL DIRECTOR, ADULT MENTAL HEALTH AND ADDICTION, GRAND RIVER HOSPITAL

More information

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview

More information

Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials

Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimer s & Dementia 4 (2008) 390 394 Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Donald J. Connor a, *, Marwan N. Sabbagh a, Jeffery L. Cummings b a Cleo

More information

Malaysian Healthy Ageing Society

Malaysian Healthy Ageing Society { Organised by: Co-Sponsored: Malaysian Healthy Ageing Society Promoting Healthy Ageing in Depressed Elderly Patients Ist World Congress On Healthy Ageing Evolution: Holistic Ageing in an Age of change

More information

Alzheimer s disease Treatment options

Alzheimer s disease Treatment options Alzheimer s disease Treatment options Treatment options Recent research has greatly improved our knowledge of Alzheimer s disease. Treatments for the disease are now available that may help to alleviate

More information

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event

More information

Psychological therapies for people with dementia who have associated depression [New 2015].

Psychological therapies for people with dementia who have associated depression [New 2015]. Psychological therapies for people with dementia who have associated depression [New 2015]. SCOPING QUESTION: For people with dementia and comorbid depression, do psychological interventions (including

More information

Safety and health training model It is expected that better recognition of hazards can reduce risks to workers. Course depth and suitable teaching met

Safety and health training model It is expected that better recognition of hazards can reduce risks to workers. Course depth and suitable teaching met Y.J. Hong, Y.H. Lin, H.H. Pai, et al DEVELOPING A SAFETY AND HEALTH TRAINING MODEL FOR PETROCHEMICAL WORKERS Yu-Jue Hong, Ya-Hsuan Lin, Hsiu-Hua Pai, 1 Yung-Chang Lai, 2 and I-Nong Lee 3 Institute of Public

More information

Original Articles. Calne, resting tremor. Mortimer, Pirozzolo, Hansch, & Webster, postural disturbance III

Original Articles. Calne, resting tremor. Mortimer, Pirozzolo, Hansch, & Webster, postural disturbance III 2004 97-106 Original Articles 1 2 3 1 1 2 3 47 22 III I II muscular rigidity postural disturbance resting tremor bradykinesia Calne, 2001 Mortimer, Pirozzolo, Hansch, & Webster, 1982 Tel: 02-23627076 E-mail:

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a preprint version which may differ from the publisher's version. For additional information about this

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a preprint version which may differ from the publisher's version. For additional information about this

More information

Welcome to the RGP of Toronto network webinar! Clinical Screening in the Geriatric Population will begin in a few moments. Here are some setup tips:

Welcome to the RGP of Toronto network webinar! Clinical Screening in the Geriatric Population will begin in a few moments. Here are some setup tips: Welcome to the RGP of Toronto network webinar! Clinical Screening in the Geriatric Population will begin in a few moments. Here are some setup tips: hover your mouse at the bottom of your screen to bring

More information

Erin Cullnan Research Assistant, University of Illinois at Chicago

Erin Cullnan Research Assistant, University of Illinois at Chicago Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,

More information

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and

More information

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI) October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine

More information

Screening Summary (SS2)

Screening Summary (SS2) 15Screening SummarySS217 Aug 06 Depression in Alzheimer s Disease Study - 2 DIADS-2 Screening Summary (SS2) Keyed: ( ) Purpose: Document findings about eligibility for DIADS-2 and about medical and social

More information

Managing agitation in dementia using non-pharmacological therapies

Managing agitation in dementia using non-pharmacological therapies Managing agitation in dementia using non-pharmacological therapies Gill Livingston Lynsey Kelly, Elanor Lewis-Holmes, Gianluca Baio, Rumana Omar, Stephen Morris, Nishma Patel, Cornelius Katona, Claudia

More information

BioScience Trends. 2018; 12(5): College of Business Administration, Shenyang Pharmaceutical University, Shenyang, China.

BioScience Trends. 2018; 12(5): College of Business Administration, Shenyang Pharmaceutical University, Shenyang, China. Policy Forum BioScience Trends. ; ():-. DOI:./bst.. China issues the National Essential Medicines List ( edition): Background, differences from previous editions, and potential issues Jiangjiang He,, Mi

More information

Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018

Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review

More information

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a

More information

The Global Impact of Dementia

The Global Impact of Dementia The Global Impact of Dementia Martin Prince No conflicts of interest Centre for Global Mental Health Health Service and Population Research Department King s College London 1066drg@iop.kcl.ac.uk Agenda

More information

K. Kahle-Wrobleski 1, J.S. Andrews 1, M. Belger 2, S. Gauthier 3, Y. Stern 4, D.M. Rentz 5, D. Galasko 6

K. Kahle-Wrobleski 1, J.S. Andrews 1, M. Belger 2, S. Gauthier 3, Y. Stern 4, D.M. Rentz 5, D. Galasko 6 The Journal of Prevention of Alzheimer s Disease - JPAD Volume 2, Number 2, 2015 Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer s Disease: Transforming Functional

More information

Dementia of the Alzheimer Type: the Drug Treatment Debate

Dementia of the Alzheimer Type: the Drug Treatment Debate Dementia of the Alzheimer Type: the Drug Treatment Debate I have no financial conflict of interest. Many years ago I was given a trip to San Fran and taught to use a slide set from the drug company. I

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

Selected Studies using the Chinese LSNS

Selected Studies using the Chinese LSNS Selected Studies using the Chinese LSNS Boey, K. W., & Chiu, H. F. K. (2005). Life strain and psychological distress of older women and older men in Hong Kong. Aging & Mental Health, 9(6), 555-562. PMID:

More information

Drug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle

Drug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Drug Update Treatments for Cognitive Impairment in the Older Adult William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Current Drug Treatments for Alzheimer s Disease Cholinesterase Inhibitors:

More information

Submission on the Draft National Clinical Practice Guidelines for Dementia in Australia

Submission on the Draft National Clinical Practice Guidelines for Dementia in Australia Submission on the Draft National Clinical Practice Guidelines for Dementia in Australia 4 June 2015 details Name of organisation Royal Australian College of General Practitioners () Postal Address Legal

More information

LTC Research Influencing Practice

LTC Research Influencing Practice LTC Research Influencing Practice David A. Nace, MD, MPH Division of Geriatric Medicine naceda@upmc.edu PGS Clinical Update April 6, 2017 Conflicts of Interest Dr. Nace does not have any current conflicts

More information

Quality of Acute Care for Older Persons with Dementia

Quality of Acute Care for Older Persons with Dementia Quality of Acute Care for Older Persons with Dementia A Hospital-Based Pilot Study Chien-Liang Liu Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taiwan 2013/04/20 Outline Background

More information

Questionnaire on National Care Pathways for People with Dementia Living at Home

Questionnaire on National Care Pathways for People with Dementia Living at Home Questionnaire on National Care Pathways for People with Dementia Living at Home 2014 YEARBOOK For queries please contact Ana Diaz: by phone 0035229797014, or by e-mail at Ana.diaz@alzheimer-europe.org

More information

Pharmacological Treatment of Dementia

Pharmacological Treatment of Dementia Pharmacological Treatment of Dementia Measure Description Percentage of patients with dementia or their caregivers with whom available guideline-appropriate pharmacological treatment options and nonpharmacological

More information

Drugs for dementia: the first year

Drugs for dementia: the first year The Ulster Medical Journal, Volume 69, No. 2, pp. 123-127, November 2000. Drugs for dementia: the first year An audit of prescribing practice G McGirr, S A Compton Accepted 12 September 2000 SUMMARY In

More information

Dementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.

Dementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health. Dementia Basics What to expect and how to handle a dementia diagnosis March 18, 2017 In partnership with Scripps Health Welcome! 1 Welcome Kristin Gaspar San Diego County Supervisor District 3 2 Our Mission:

More information

Evaluations. Alzheimer s Disease A Public Health Response. Viewer Call-In. July 19, Guest Speakers. Thanks to our Sponsors:

Evaluations. Alzheimer s Disease A Public Health Response.   Viewer Call-In. July 19, Guest Speakers. Thanks to our Sponsors: Alzheimer s Disease A Public Health Response July 19, 2007 1 2 Guest Speakers Thanks to our Sponsors: Earl A. Zimmerman, M.D. Bender Endowed Chair of Neurology and Director of the Alzheimer s Center at

More information

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there

More information

Critical Review: Does reminiscence therapy including life story work improve the quality of life of people with dementia?

Critical Review: Does reminiscence therapy including life story work improve the quality of life of people with dementia? Critical Review: Does reminiscence therapy including life story work improve the quality of life of people with dementia? Tiffany Ashford M.Cl.Sc (SLP) Candidate University of Western Ontario: School of

More information

PMDA Considerations for Outcome Assessments

PMDA Considerations for Outcome Assessments PMDA Considerations for Outcome Assessments Keiju Motohashi Office of New Drug II Pharmaceuticals and Medical Devices Agency/ The University of Tokyo Hospital Disclaimer The views and opinions expressed

More information

Gerardo Machnicki 1, Ricardo F. Allegri 1,2 *, Carol Dillon 1, Cecilia M. Serrano 1,2 and Fernando E Taragano 2 SUMMARY INTRODUCTION

Gerardo Machnicki 1, Ricardo F. Allegri 1,2 *, Carol Dillon 1, Cecilia M. Serrano 1,2 and Fernando E Taragano 2 SUMMARY INTRODUCTION INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry (2008) Published online in Wiley InterScience (www.interscience.wiley.com).2133 Cognitive, functional and behavioral factors associated

More information

ORIGINAL CONTRIBUTION. Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment

ORIGINAL CONTRIBUTION. Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment ORIGINAL CONTRIBUTION Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment David F. Tang-Wai, MDCM; David S. Knopman, MD; Yonas E. Geda, MD;

More information

The place for treatments of associated neuropsychiatric and other symptoms

The place for treatments of associated neuropsychiatric and other symptoms The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public

More information

DEMENTIA NEWSLETTER for PHYSICIANS

DEMENTIA NEWSLETTER for PHYSICIANS DEMENTIA NEWSLETTER for PHYSICIANS Vol. 6, No. 4 OTTAWA AND RENFREW COUNTY Winter 2008 In This Issue... Mild Cognitive Impairment Monitoring Patient Response to Cognitive Enhancers CDN Diagnostic Assessment

More information

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) A. The development of multiple cognitive deficits manifested by both 1 and 2 1 1. Memory impairment 2. One (or more) of the following

More information

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top

More information

Nutritional interventions for the prevention of cognitive impairment and dementia in East Asia. A systematic review (and meta-analysis)

Nutritional interventions for the prevention of cognitive impairment and dementia in East Asia. A systematic review (and meta-analysis) Nutritional interventions for the prevention of cognitive impairment and dementia in East Asia A systematic review (and meta-analysis) Aim and objectives The aim of this systematic review is to evaluate

More information

Anosognosia, or loss of insight into one s cognitive

Anosognosia, or loss of insight into one s cognitive REGULAR ARTICLES Anosognosia Is a Significant Predictor of Apathy in Alzheimer s Disease Sergio E. Starkstein, M.D., Ph.D. Simone Brockman, M.A. David Bruce, M.D. Gustavo Petracca, M.D. Anosognosia and

More information

Form A3: Subject Family History

Form A3: Subject Family History Initial Visit Packet NACC Uniform Data Set (UDS) Form A: Subject Family History ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by a clinician

More information

Depression among elderly attending geriatric clubs in Assiut City, Egypt

Depression among elderly attending geriatric clubs in Assiut City, Egypt Depression among elderly attending geriatric clubs in Assiut City, Egypt Eman M. Mohamed *1, Mohamed A Abd-Elhamed 2 1 Public Health and Community Medicine Dept., Faculty of Medicine, Assiut University

More information

Promotion of Mental Health in Older People

Promotion of Mental Health in Older People Promotion of Mental Health in Older People Helen Chiu Professor, Department of Psychiatry, CUHK President, Hong Kong Psychogeriatric Association Past President, International Psychogeriatric Association

More information

CTFPHC Working Group Members:

CTFPHC Working Group Members: Cognitive Impairment - Guideline Presentation Speaker deck OVERVIEW We will review the following: 1. Background on Cognitive Impairment 2. Methods of the CTFPHC 3. Recommendations and Key Findings 4. Implementation

More information

Thesis for doctoral degree (Ph.D.) 2007 Predictors of cognitive decline in memory clinic patients. Christin Andersson. Christin Andersson

Thesis for doctoral degree (Ph.D.) 2007 Predictors of cognitive decline in memory clinic patients. Christin Andersson. Christin Andersson Thesis for doctoral degree (Ph.D.) 2007 Thesis for doctoral degree (Ph.D.) 2007 Predictors of cognitive decline in memory clinic patients Christin Andersson Predictors of cognitive decline in memory clinic

More information

Medications for Alzheimer s disease: are they right for you?

Medications for Alzheimer s disease: are they right for you? Medications for Alzheimer s disease: are they right for you? There are no medications today that can cure Alzheimer s disease. But there are currently four medications approved by Health Canada which can

More information

Scientific publications in critical care medicine journals from East Asia: A 10-year survey of the literature

Scientific publications in critical care medicine journals from East Asia: A 10-year survey of the literature Open Access Original Article Scientific publications in critical care medicine journals from East Asia: A 10-year survey of the literature Zhenyu Cao 1, Chongyang Ou 2, Hongfei Teng 3, Xiguang Liu 4, Hongxin

More information

Alzheimer Disease Agents Drug Class Prior Authorization Protocol

Alzheimer Disease Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Alzheimer Disease Agents Drug Class Prior Authorization Protocol This policy has been developed through review

More information

Recognizing Dementia can be Tricky

Recognizing Dementia can be Tricky Dementia Abstract Recognizing Dementia can be Tricky Dementia is characterized by multiple cognitive impairments that cause significant functional decline. Based on this brief definition, the initial expectation

More information

Consultation response form: Together for a Dementia Friendly Wales ( ) Proposed Together for a Dementia Friendly Wales ( )

Consultation response form: Together for a Dementia Friendly Wales ( ) Proposed Together for a Dementia Friendly Wales ( ) Consultation response form: Together for a Dementia Friendly Wales (2017-22) Overview Proposed Together for a Dementia Friendly Wales (2017-22) How to respond Responses should be submitted by 3 April 2017

More information

Not skilled at all Beginning skill Moderate skill Advanced skill Expert skill

Not skilled at all Beginning skill Moderate skill Advanced skill Expert skill Geriatric Social Work Competency Scale II with Life-long Learning in Relationship to Leadership s: Social Work Practice Behaviors in the Field of Aging The following is a listing of skills recognized by

More information

Appendix 2 (continued): Recommendations for the management of mild to moderate dementia, dementia with a cerebrovascular component, and for addressing

Appendix 2 (continued): Recommendations for the management of mild to moderate dementia, dementia with a cerebrovascular component, and for addressing a cerebrovascular component, and for addressing ethical issues in dementia (page 1 of 7) Mild to moderate dementia 1. Most patients with dementia can be assessed and managed adequately by their primary

More information

Day Care Center for Patients with Dementia. Athens Association of Alzheimer s Disease and Related Disorders

Day Care Center for Patients with Dementia. Athens Association of Alzheimer s Disease and Related Disorders Day Care Center for Patients with Dementia Athens Association of Alzheimer s Disease and Related Disorders What about A.D. in Greece? 160.000 people are suffering from A.D. in Greece.. This number is expected

More information

2017 ALZHEIMER'S DISEASE FACTS AND FIGURES

2017 ALZHEIMER'S DISEASE FACTS AND FIGURES Page 1 of 5 2017 ALZHEIMER'S DISEASE FACTS AND FIGURES By Diana Iuliano-Chan, Region IV NARFE-Alzheimer's Regional Coordinator. The number of Americans living with Alzheimer's disease is growing and growing

More information

The Development and Validation of Korean Dementia Screening Questionnaire (KDSQ)

The Development and Validation of Korean Dementia Screening Questionnaire (KDSQ) The Development and Validation of Korean Dementia Screening Questionnaire (KDSQ) Dong Won Yang, M.D., Belong Cho, M.D.*, Jean Yung Chey, Ph.D., Sang Yun Kim, M.D., Beum Saeng Kim, M.D. Department of Neurology,

More information